Success Metrics

Clinical Success Rate
93.8%

Based on 15 completed trials

Completion Rate
94%(15/16)
Active Trials
1(5%)
Results Posted
40%(6 trials)
Terminated
1(5%)

Phase Distribution

Ph phase_2
4
20%
Ph early_phase_1
1
5%
Ph phase_1
6
30%
Ph phase_3
4
20%
Ph not_applicable
2
10%
Ph phase_4
2
10%

Phase Distribution

7

Early Stage

4

Mid Stage

6

Late Stage

Phase Distribution19 total trials
Early Phase 1First-in-human
1(5.3%)
Phase 1Safety & dosage
6(31.6%)
Phase 2Efficacy & side effects
4(21.1%)
Phase 3Large-scale testing
4(21.1%)
Phase 4Post-market surveillance
2(10.5%)
N/ANon-phased studies
2(10.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

93.8%

15 of 16 finished

Non-Completion Rate

6.3%

1 ended early

Currently Active

1

trials recruiting

Total Trials

20

all time

Status Distribution
Active(2)
Completed(15)
Terminated(1)
Other(2)

Detailed Status

Completed15
unknown2
Terminated1
Recruiting1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
20
Active
1
Success Rate
93.8%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (5.3%)
Phase 16 (31.6%)
Phase 24 (21.1%)
Phase 34 (21.1%)
Phase 42 (10.5%)
N/A2 (10.5%)

Trials by Status

completed1575%
terminated15%
recruiting15%
not_yet_recruiting15%
unknown210%

Recent Activity

Clinical Trials (20)

Showing 20 of 20 trials
NCT04713358Phase 4

Effect of Nalmefene on the Quality of Resuscitation in Patients Under General Anesthesia

Completed
NCT02639273Phase 1

Title: Effect of Opioid Receptor Modulation on Alcohol Self-Administration and Neural Response to Alcohol Cues in Heavy Drinkers: Role of OPRM1 Gene Variation

Completed
NCT06733519Phase 2

TH104 for the Treatment of Pruritus in Primary Biliary Cholangitis

Not Yet Recruiting
NCT06198686Phase 1

An Evaluation of The Absolute Bioavailability of TH104

Completed
NCT05540288Phase 3

NAlmefene Versus Placebo in Addition to Treatment as Usual on Craving in Behavioural Addictions

Recruiting
NCT04759768Phase 1

Pharmacokinetic Evaluation of Intranasal Nalmefene

Completed
NCT03096730Not Applicable

Effect of Dexmedetomidine Combined With Low-dose Nalmefene on Preventing Remifentanil-induced Postoperative Hyperalgesia

Completed
NCT03279562Phase 1

Patient Driven Recovery With Nalmefene and Coaching

Completed
NCT03034408Phase 2

Nalmefene, Baclofen and Impulsivity in Subjects With Alcohol Use Disorder and Healthy Control Subjects

Completed
NCT03278886Phase 1

St. PETERsburg Pain and Alcohol Intervention With Naltrexone and Nalmefene

Completed
NCT02492581

Use of Selincro and Impact on Usual Practice

Completed
NCT03129347Phase 1

Pharmacokinetic Evaluation of Nalmefene Administered Intranasally to Healthy Volunteers

Completed
NCT02372318Early Phase 1

Single-dose of Nalmefene to Modulate Neural Alcohol Cue Reactivity

Terminated
NCT02197598Phase 4

Treatment of Patients Suffering of Alcohol Dependence and Impaired Liver Function With Selincro® As-needed Use

Completed
NCT02934919Phase 2

Evaluation of Nalmefene in Impulse Control Disorders in Parkinson's Disease: A Prospective Open Label Study

Unknown
NCT02752503Not Applicable

Nalmefene in Alcohol Dependence and Borderline Personality Disorder

Unknown
NCT00811941Phase 3

Safety and Efficacy of Nalmefene in Patients With Alcohol Dependence

Completed
NCT00812461Phase 3

Efficacy of Nalmefene in Patients With Alcohol Dependence

Completed
NCT00811720Phase 3

Efficacy of Nalmefene in Patients With Alcohol Dependence

Completed
NCT00202696Phase 2

Nalmefene Smoking Cessation Study

Completed

All 20 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
20